Please login to the form below
HTA guidance from NICE, the SMC and the AWMSG
Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).
Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.
NICE managing COVID-19 guideline
Summary of NICE guidance on the management of COVID-19 in children, young people, and adults in primary care settings
Published: 27 Jun 2022
UKHSA monkeypox guidance
Providing information and advice for healthcare professionals on monkeypox. Includes vaccination recommendations and a useful contact tracing table
Published: 21 Jun 2022
Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure
This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
Published: 20 May 2022
NICE epilepsies guideline
Covering diagnosing and managing epilepsy in children, young people, and adults
Published: 13 May 2022
NHS statin intolerance pathway
A Guidelines summary covering the definition, classification, and management of statin intolerance
Published: 04 May 2022
UKHSA HPV vaccination guidance
Summary of adolescent and MSM HPV vaccination guidance with updated (March 2022) recommendations on dosing
Published: 04 May 2022
NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
1 Jul 2022
The National Institute for Health and Care Excellence (NICE) has issued a final draft recommendation for Novartis Pharmaceuticals UK’s Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukaemia ... NICE’s
NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
30 Jun 2022
The decision from NICE follows a multiple technology appraisal (MTA) and its recommendation simultaneously approves Adtralza, Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for reimbursement following use in NHS England and Wales, which ... NICE based
Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer
17 Jun 2022
Eli Lilly’s Verzenios (abemaciclib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for early-stage breast cancer in combination with endocrine therapy. ... The NICE approval of Verzenios in
NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales
10 Jun 2022
Amarin’s Vazkepa (icosapent ethyl) has been recommended by the National Institute for Health and Care Excellence (NICE) for adults receiving statin treatment who are deemed to be at high cardiovascular ... Vazkepa is a new active substance, made up of
NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
26 May 2022
NICE’s decision was based on positive results from the EMPOWER-CSCC-1 trial. ... NICE first recommended that Libtayo should be made available through the Cancer Drugs Fund (CDF) in 2019.
MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.
To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
